The Authors report their experience with interleukin 2 given intralesionally and subcutaneously in superficial bladder tumours after transurethral resection. The present study was carried out to evaluate the efficacy and tollerability of a subcutaneous immunotherapy with IL-2 in these tumours.
The study included 16 patients with superficial bladder cancer (Ta-T1 G1-G2) and it showed that IL-2 is an effective and well-tolerated treatment of superficial bladder cancer but a longer follow-up period is necessary.
WestW.H., TauerK.W., YannelliJ.R., MarshallG.D., OrrD.W., ThurmanG.B., OldhamR.K.: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. England J. Med., 316: 898–905, 1987.
3.
Tubaro: Endovesical IL-2 in the treatment of low stage bladder cancer. Vol. 149: 357, 1993.
